Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) and Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.
Profitability
This table compares Enanta Pharmaceuticals and Oruka Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enanta Pharmaceuticals | -141.98% | -89.02% | -27.28% |
| Oruka Therapeutics | N/A | -26.26% | -24.16% |
Analyst Ratings
This is a breakdown of current ratings and price targets for Enanta Pharmaceuticals and Oruka Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enanta Pharmaceuticals | 1 | 0 | 6 | 0 | 2.71 |
| Oruka Therapeutics | 1 | 0 | 4 | 1 | 2.83 |
Risk and Volatility
Enanta Pharmaceuticals has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.29, suggesting that its share price is 129% less volatile than the S&P 500.
Institutional & Insider Ownership
95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 13.9% of Enanta Pharmaceuticals shares are held by company insiders. Comparatively, 24.7% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Enanta Pharmaceuticals and Oruka Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enanta Pharmaceuticals | $67.64 million | 3.51 | -$116.04 million | ($4.32) | -2.57 |
| Oruka Therapeutics | N/A | N/A | -$83.72 million | ($2.81) | -9.78 |
Oruka Therapeutics has lower revenue, but higher earnings than Enanta Pharmaceuticals. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Oruka Therapeutics beats Enanta Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
About Oruka Therapeutics
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
